The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pharmacogenomic scoring system predicting median time to progression (mTTP) on sunitinib (SUN) as first-line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC).
Benoit Beuselinck
No relevant relationships to disclose
Alexandra Karadimou
No relevant relationships to disclose
Gabrielle Couchy
No relevant relationships to disclose
Bart Claes
No relevant relationships to disclose
Diether Lambrechts
No relevant relationships to disclose
Joost Berkers
No relevant relationships to disclose
Robert Paridaens
No relevant relationships to disclose
Patrick Schoffski
No relevant relationships to disclose
Hendrik Van Poppel
No relevant relationships to disclose
Pascal Wolter
No relevant relationships to disclose
Mejean Arnaud
No relevant relationships to disclose
Evelyne Lerut
No relevant relationships to disclose
Brigitte Laguerre
No relevant relationships to disclose
Christine Theodore
No relevant relationships to disclose
Claude Linassier
No relevant relationships to disclose
Remy Delva
No relevant relationships to disclose
Emmanuel Sevin
No relevant relationships to disclose
Francois Goldwasser
No relevant relationships to disclose
Jessica Zucman-Rossi
No relevant relationships to disclose
Stephane Oudard
No relevant relationships to disclose